Oppenheimer Reiterates “Buy” Rating for TherapeuticsMD (TXMD)

Oppenheimer reaffirmed their buy rating on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Wednesday.

Other analysts also recently issued research reports about the company. BidaskClub upgraded TherapeuticsMD from a strong sell rating to a sell rating in a research report on Friday, February 9th. Noble Financial restated a buy rating on shares of TherapeuticsMD in a research report on Thursday, February 22nd. Deutsche Bank set a $9.00 target price on TherapeuticsMD and gave the stock a buy rating in a research report on Wednesday, December 20th. Finally, Cantor Fitzgerald restated a buy rating and issued a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD has an average rating of Buy and an average target price of $14.50.

How to Become a New Pot Stock Millionaire

TXMD stock opened at $4.96 on Wednesday. The company has a market capitalization of $1,120.95, a PE ratio of -13.05 and a beta of 1.36. TherapeuticsMD has a twelve month low of $3.50 and a twelve month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.01). The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The business’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) EPS. analysts anticipate that TherapeuticsMD will post -0.38 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. lifted its position in TherapeuticsMD by 26.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock valued at $756,000 after purchasing an additional 30,030 shares during the last quarter. Swiss National Bank lifted its position in TherapeuticsMD by 12.3% in the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock valued at $1,533,000 after purchasing an additional 31,800 shares during the last quarter. Bank of New York Mellon Corp lifted its position in TherapeuticsMD by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock valued at $136,894,000 after purchasing an additional 2,985,846 shares during the last quarter. GSA Capital Partners LLP bought a new stake in TherapeuticsMD in the third quarter valued at approximately $528,000. Finally, Greenwood Capital Associates LLC lifted its position in TherapeuticsMD by 25.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 74,268 shares of the company’s stock valued at $449,000 after purchasing an additional 15,300 shares during the last quarter. Hedge funds and other institutional investors own 73.27% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3296229/oppenheimer-reiterates-buy-rating-for-therapeuticsmd-txmd-2.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cavco Industries  Stock Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cavco Industries Stock Price
Inter Parfums  Earning Somewhat Positive Media Coverage, Report Finds
Inter Parfums Earning Somewhat Positive Media Coverage, Report Finds
Varian Medical Systems  SVP Sells $161,936.32 in Stock
Varian Medical Systems SVP Sells $161,936.32 in Stock
Insider Selling: Workday, Inc.  Insider Sells $195,806.70 in Stock
Insider Selling: Workday, Inc. Insider Sells $195,806.70 in Stock
ASOS.com  vs. Cato  Head to Head Survey
ASOS.com vs. Cato Head to Head Survey
Tahoe Resources  Earning Somewhat Positive News Coverage, Report Finds
Tahoe Resources Earning Somewhat Positive News Coverage, Report Finds


© 2006-2018 Ticker Report. Google+.